Nuxe has been acquired by NAXICAP Partners
The shareholders of Nuxe have sold the company to NAXICAP Partners for US$66 million.
Nuxe manufactures natural cosmetics and skin and hair care products and is one of the most dynamic players in the market for natural cosmetics in pharmacies and paraphamacies. The company is headquartered in France and has 260 employees.
NAXICAP Partners is an investment firm specializing in direct and fund of fund investments. It focuses on start-ups, venture capital, growth capital, and middle-market investments, expansion capital, turnarounds, reorganization of capital ownership, funding post early-stage company creations, and buyout transactions such as leveraged buyouts, owner's buyouts, management buyouts, and management buyins. NAXICAP Partners has been a responsible and committed financial partner for companies for over 30 years, has approximately US$600 million of capital under management and is now one of the leading providers of equity financing for businesses in France.
Oaklins' team in France advised the seller in this transaction.
Talk to the deal team
Related deals
Salmo Group has acquired SAENGER Top Tackle and Westline Angelgeräte
Salmo Group SIA, a Riga-based family-owned fishing products vendor, has acquired SAENGER Top Tackle GmbH and Westline Angelgeräte GmbH, German wholesale distributors of fishing tackle across Western Europe.
Learn moreRare Patient Voice has been acquired by Konovo
Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.
Learn moreLindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn more